The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market
The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market after securing additional fundinglater this year, according to vice president John Haytaian.
Magna-Lab failed to meet NASDAQ's net worth requirement of$1 million for the small-cap market after a private equity placementfell through late last year and the company began using debt tofund operations (SCAN 12/14/94). NASDAQ made the decision to moveMagna-Lab's stock earlier this month. Ironically, Magna-Lab'sstock began moving upward after the move, Haytaian said.
Magna-Lab signed a letter of intent this month for a secondarypublic offering of $5 million to take place in the next two tothree months that will bring the company back into compliancewith NASDAQ requirements. The firm may also complete a privateequity placement by then, according to Haytaian.
The company has been rounding out its stable of distributionpartners for the Magna-SL 0.3-tesla scanner, which received Foodand Drug Administration clearance last year (SCAN 9/28/94). Magna-Labthis month signed an agreement with American Medical Concepts(AMCI) of Houston to distribute Magna-SL to the U.S. orthopedicmarket. The deal will complement an agreement with Beta-Numericsfor the fee-per-scan and mobile markets, as well as a deal withElscint for international sales that has not yet been finalized.
Magna-Lab this month completed the first installation of Magna-SLto MedCenter Imaging in San Antonio, TX. The installation tookonly two days, Haytaian said. Imaging services firm Health Imagesof Atlanta will be under contract by Magna-Lab to provide servicefor that unit, he said.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.